As the Healthcare sector emerges from a time of immense pressure and high visibility, we see huge investment, potential and opportunity ahead

Truly dynamic and innovative at its core, Healthcare is poised for a period of growth and transformation. Driven by a range of factors – including Covid-19; greater emphasis on personalisation; digitisation and technological innovation; changing demographics; and shifting customer and patient expectations – organisations of all sizes and ownership structures seek the right leaders to seize this opportunity.

Supporting clients at Board, Executive Committee and leadership levels, we combine extensive experience in and a deep understanding of the wide and varied Healthcare sector, including its clinical leadership, as well as access to relevant talent pools in adjacent consumer-facing industries.

View current opportunities

The MBS Group acts as an advisor to NHS and other public sector bodies on senior appointments. To view current appointments, click here.

Our Experience

Clinical Services
HealthTech & Digital Healthcare
Healthcare Systems
Life Sciences
Medical Devices & Diagnostics

Selected Clients

Key People

Hatty Cadman

Hatty Cadman


Moira Benigson

Moira Benigson

Founder & Chair

Elliott Goldstein

Elliott Goldstein

Managing Partner

Latest MBS News & Intelligence

MBS News

9 August 2022 - 17:20

Glasgow uni medtech spin-out secures £1m funding University of Glasgow spin-out Acu-Flow has secured a £1m grant to help bring its tech for treating respiratory diseases to market. The funding will help the Acu-Flow team to develop a fully-integrated nebuliser, ready to take to large-scale manufacture. Read more.

9 August 2022 - 17:14

Sofia Angels Ventures helps UK medtech startup Digistain raise $1m to fight breast cancer The venture fund supported by European Investment Fund for angel and private co-investment, Sofia Angels Ventures announced that it had made its fourth investment, backing UK-based medtech startup Digistain. Read more.

8 August 2022 - 17:54

Pfizer buys Global Blood Therapeutics for £4.4bn Pfizer has bought Global Blood Therapeutics for $5.4bn, as the US pharmaceutical giant continues strengthening its sickle cell disease expertise. Read more.